When is the microfiltration of whole blood and red cell concentrates essential? When is it superfluous?

Massive blood transfusion

Pediatricians in the hospital setting must frequently treat children who require massive transfusion (MT) in a variety of clinical situations ranging from major trauma to neonatal hyperbilirubinemia. After identifying the need for massive transfusion, the pediatrician must select the appropriate blood components. Different blood components have specific temperature, preservative, and time requirements for their storage. Changes, termed storage lesions, occur over time in blood components during storage; biochemical changes include decreased levels of 2,3-DPG, a decrease in pH, and an increase in supernatant potassium (K+) with a concurrent decrease in intracellular K+. These changes may affect the function and the viability of components. Additionally, physical changes such as deformation of the red cell membrane occur during storage. Knowledge of these storage lesions is necessary for the pediatrician to make the most appropriate decisions regarding the preparation and selection of components during MT. Serious complications of MT include hemostatic abnormalities, biochemical/metabolic abnormalities, hypothermia, mechanical injury and the effect of Rh incompatibility, each of which has a specific management response. Pediatricians need to be aware of the potential complications associated with massive transfusion, to take measures to prevent them when possible, to anticipate additional transfusion requirements, and to know how to manage them in the pediatric patient.

Massive blood transfusion: the blood bank perspective

The pathophysiology and support of the massively transfused patient from the vantage of a blood banker is reviewed. Hypothermia, acidosis and shock must be reversed if blood component therapy is to be effective. Algorithms which employ ratios of various blood components have not proved themselves, nor are screening coagulation tests of value until they are remarkably abnormal. Thrombocytopenia, thrombocytopathy, and hypofibrinogenemia appear to be the parameters which predispose to continued bleeding and microvascular hemorrhage in these patients. A large part of the impaired hemostasis is due to a consumption coagulopathy rather than the anecdotal assumption that dilution of the hemostatic elements is to blame. Hypocalcemia, hypomagnesemia and hyperkalemia are rarely observed nor do they pose a problem for this group of individuals. The logistics of blood supply to the clinical areas are addressed by describing one system that has proved itself.

The role of blood microfilters in clinical practice

Blood filters have been available since the 1930s. In this review we evaluate the role of microaggregate filters (MF) in certain transfusion complications, namely non-haemolytic febrile transfusion reactions (NHFTR), pulmonary injury, thrombocytopenia, fibronectin depletion and histamine release. We review the latest generation of leucocyte depleting filters and discuss their role in preventing alloimmunisation, immunosuppression and CMV transmission. Finally, we provide a rationale for the role of blood microfiltration in the present day practice of intensive care medicine.

[Multicenter study on the efficacy of leukocyte depletion by filtration of red cells. The Labile Blood Products Group]

To determine the actual efficacy of red cells filtration technique, the "Labile Blood Component Production" french study group, including 21 blood centers, realized a large study on more than 1,400 filtrations and 3,000 controls. 745 units of red cell concentrates (RCC) and 690 units of buffy-coat poor red blood cells (BC PRBC) were filtered through 6 commercialized leukocytes depleting filters: not less than 170 experiments per filter, tested by 3 different blood centers. Pre-filtration controls prove that buffy-coat removal, done manually or with automated equipment, involves a first leukocytes depletion about 63% and an hemoglobin loss equal to 4 g (7%). After filtration, residual leukocytes counts were performed manually in a Nageotte counting chamber. In this study, we evaluated the reliability of this simple method which accurately measures very low leukocytes counts. The variation coefficient was 25% for 2.5 leukocytes/microliter concentration (O.6 x 10(6) per filtered unit). The results, obtained from 1200 evaluated filtrations, confirm that buffy-coat removal obviously improves the filtration performances (residual leukocytes level is lower than 1 x 10(6) per unit for 78% filtered BC PRBC versus 43% filtered RCC). Furthermore, 90% of overall filtered units are containing less than 5 x 10(6) leukocytes.

[Technical constraints in rapid vascular fluid replacement]

Rapid fluid infusion remains the cornerstone for therapy of hypovolaemic shock. The principal limitations of flow rate are governed by the four variables of Poiseuille's law: tube internal diameter and length, viscosity of the fluid passing through the tube, and the pressure gradient between the two ends of the tube. Conventional transfusion systems, with wide bore tubing (up to 5.0 mm internal diameter), large bore cannulas (8.5 French introducer catheters), high pressure (up to 300 mmHg) and diluted blood, can result in a maximum flow rate of about 1,000 ml.min-1 (for crystalloid solutions). Specific apparatus for rapid infusion can increase this to 1,500 ml.min-1 (Rapid Infusion System, Haemonetics). Dry-heat warming devices and microfiltration, to remove microaggregates and prevent non haemolytic febrile transfusion reactions, seem necessary when carrying out rapid transfusions. However, the use of microaggregate filters could be avoided by the routine production of leukocyte-poor red blood cell concentrates.

Clinical evaluation of commonly used blood administration sets

Five commonly available blood transfusion sets, the Fenwall Blood Recipient set, the Abbott HEMAR Y-type Blood Set, the Bentley Infusion Blood Set (PFF-100), the Medex Hi-Flo TraumaR Quad Set (MX 884) and the Pall Ultipor Transfusion Set with Filter are compared. Flow rates and lifespan are evaluated by measuring the time required for 150 mL aliquots of homogeneous units of human red blood cells to pass through the devices under 300 mmHg constant pressure. Microfiltration of blood is briefly reviewed.

[Viability of human red blood cells preserved for 35 days after leukocyte depletion (in vitro study)]

24 leukocyte poor red cells concentrates (L.P.R.C.) were prepared by sterile connection of a leucocyte filter between the primary bag and the SAGM bag of a blood unit after centrifugation. Their quality was followed up to 42 days by means of a panel of tests including, ATP and 2,3-DPG levels, hemolysis, plasma potassium, lactate and glucose, and counts of the microaggregates. 24 standard units acted as a control group. Results showed better preservation of LPRC and especially less hemolysis, higher ATP levels and at least equal oxyphoric capacity (explored by 2,3-DPG). Microaggregate formation was dramatically reduced and bacteriologic checks (48 at day 25 and 48 at day 42) were all negative. Leucocyte depletion appears as a new way to improve functionality of erythrocytes during storage in the SAGM medium. 35 days shelf life will allow this blood product to be more available and its preparation more standardised.

Transfusion therapy in emergency medicine

Volume replacement is critical to the resuscitation of the hemorrhaging patient, but this usually can be accomplished quickly and safely with crystalloid and/or colloid solutions. Red cells should be used in addition to asanguinous fluids in the treatment of tissue hypoxia due to anemia. The need for whole blood as opposed to packed red blood cells is controversial. However, plasma should not be used as a volume expander, and its use to supplement coagulation factors during the massive transfusion of red cells should be guided by laboratory tests that document a coagulopathy. Similarly, platelet transfusions are indicated to correct documented thrombocytopenia or platelet dysfunction, and routine prophylaxis after fixed volumes of red cells results is unwarranted. Many anticipated complications of massive transfusions, including hemostatic abnormalities, acid-base imbalances, hyperkalemia, and hypocalcemia, are uncommon or of limited clinical significance. The risks of immune hemolysis and transfusion-transmitted diseases, on the other hand, are significant, and argue for judicious use of blood components. In emergencies in which blood is required immediately before compatibility testing can be completed, O-negative uncrossmatched blood can be requested. Careful blood specimen collection and patient identification prior to transfusion are critical. Practices that emphasize blood conservation, including the use of autologous salvaged blood, are always to the patient's advantage.